Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Mersana Therapeutics, Inc. (MRSN)
P/E ratio as of 2023: -1.57
According to Mersana Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.57. At the end of 2022 the company had a P/E ratio of -2.64.
P/E ratio history for Mersana Therapeutics, Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.57 |
| 2022 | -2.64 |
| 2021 | -2.59 |
| 2020 | -18.51 |
| 2019 | -9.14 |
| 2018 | -1.46 |
| 2017 | -5.10 |
| 2016 | -17.88 |
| 2015 | -14.91 |